|  |
| --- |
|  |

|  |
| --- |
| **TOCCV1\_ver3.0 Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)** |
| **Patient NHS No:** |   | **Trust:** |   |
| **Patient Hospital No:** |  \* | **Practice Code:** |   |
| **Patient's Initials and DoB:** |   | **GP Postcode:** |   |
| **Choose Consultant:** |

|  |  |
| --- | --- |
|  | select |

 help |
| **Consultant Name:** |   \* | **Other Contact Details:** |   \* |
| **Notification Email Address:**  (@NHS.net account ONLY) |
| **Treatment Start Date:** |   Clear selected value   \* |
|  |

|  |  |
| --- | --- |
| **Please indicate whether patient meets the following criteria:** | **Please tick** |
| 1. I confirm that the patient is an adult with SARS-CoV-2 infection\*\* In the absence of a confirmed virological diagnosis, tocilizumab should only be used when a multidisciplinary team have a high level of confidence that the clinical and radiological features suggest that COVID-19 is the most likely diagnosis. |

|  |
| --- |
| Yes |
| No |

\* Required |
| 2. I confirm intravenous tocilizumab has been prescribed as the patient is an adult who has been admitted to ICU with severe pneumonia requiring respiratory support\*\*, such as high-flow nasal oxygen, CPAP or non-invasive ventilation, or invasive mechanical ventilation and **all** of the following apply:• No more than 24 hours has elapsed since ICU admission or more than 24 hours after starting respiratory support (whichever is the later)• The patient will receive tocilizumab according to the Interim Position Statement: IL-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)\*\*\* and does not meet any of the exclusion criteria• The patient will receive a maximum number of two doses\*\* Or admitted to ICU with organ failure requiring support as infusion of vasopressor or inotropes or both\*\*\* As part of the interim position statement hospitals are strongly encouraged to submit data through the ISARIC 4C Clinical Characterisation Protocol (CCP) case report forms (CRFs), as coordinated by the COVID-19 Clinical Information Network (CO-CIN)**NB: For adult patients with SARS-CoV-2 infection who have not been admitted to ICU, sites should consider randomisation to the immunomodulator arm in the RECOVERY trial if this is available** |

|  |
| --- |
| Yes |
| No |

\* Required |